Amid tough competition, Novartis makes case for rheumatology drug Cosentyx

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete more strongly with older drugs such as AbbVie’s Humira in this surprisingly common illness.